MRVI · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Maravai LifeSciences Holdings, Inc. (the “Company,” "Maravai," "we" or "our") has determined that it is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date of March 3, 2025, as explained below. First, the Company has not yet completed its assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC and a potential non-cash charge related to excess and obsolete inventory for Alphazyme. The Company needs additional time to complete the goodwill impairment and inventory assessment and to report the results of this analysis in its consolidated financial statements. Based on the Company’s preliminary assessment of the goodwill impairment, a non-cash goodwill impairment charge of approximately $12 million is expected to be recorded for the fourth quarter of 2024 and the Company is not yet able to make a reasonable estimate of the non-cash charge for excess and obsolete inventory. Second, the Company identified an error during the year-end financial close process with respect to revenue recognition associated with a single shipment that resulted in approximately $3.9 million in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer. The Company needs additional time to complete its assessment of the impact of correcting this error in its consolidated financial statements, which assessment must be completed prior to the filing of the 2024 Form 10-K. In connection with the foregoing matters, the Company is continuing to assess the effectiveness of its disclosure controls and procedures and internal controls over financial reporting
NT 10-K, filed 2025-03-04 · acquisition or merger
2025-07-18auditor changed or resigned SEC →
2025-03-18accounts declared unreliable SEC →
Maravai LifeSciences Holdings, Inc. (the “Company,” "Maravai," "we" or "our") has determined that it is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date of March 3, 2025, as explained below. First, the Company has not yet completed its assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC and a potential non-cash charge related to excess and obsolete inventory for Alphazyme. The Company needs additional time to complete the goodwill impairment and inventory assessment and to report the results of this analysis in its consolidated financial statements. Based on the Company’s preliminary assessment of the goodwill impairment, a non-cash goodwill impairment charge of approximately $12 million is expected to be recorded for the fourth quarter of 2024 and the Company is not yet able to make a reasonable estimate of the non-cash charge for excess and obsolete inventory. Second, the Company identified an error during the year-end financial close process with respect to revenue recognition associated with a single shipment that resulted in approximately $3.9 million in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer. The Company needs additional time to complete its assessment of the impact of correcting this error in its consolidated financial statements, which assessment must be completed prior to the filing of the 2024 Form 10-K. In connection with the foregoing matters, the Company is continuing to assess the effectiveness of its disclosure controls and procedures and internal controls over financial reporting
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice